HYBRID EVENT: Join us in person in London, UK or attend virtually from anywhere.

2nd Edition of International Conference on Gastroenterology

September 24-26, 2026, London,UK

September 24 -26, 2026 | London, UK

Policies and approval of GI drugs

Policies and approval of GI drugs

Gastrointestinal (GI) drugs are medications used to treat conditions related to the digestive system. These drugs work to reduce inflammation, control acid production, and reduce symptoms such as abdominal pain, cramping, and diarrhea. The approval and regulation of GI drugs is a complex process that involves multiple government agencies. In the United States, the Food and Drug Administration (FDA) is responsible for evaluating new drugs for safety and efficacy before they are approved for use. After the FDA reviews a drug and finds it to be safe and effective for its intended use, the agency will issue an approval for its marketing. This approval includes a Drug Facts Label which contains important information about the drug including its side effects and warnings. In addition to the FDA, the Centers for Medicare and Medicaid Services (CMS) also has an important role in the approval process for GI drugs. CMS evaluates the cost effectiveness of drugs that are approved by the FDA. This means that the agency will consider the drug’s cost versus its benefit when determining whether to approve its use. CMS may also establish reimbursement policies that affect the cost of the drug and its availability to patients. In order to ensure that GI drugs are used safely and appropriately, the FDA also has regulations in place that govern the manufacturing, labeling, advertising, and distribution of these drugs. The agency also inspects drug manufacturing facilities to make sure that they are in compliance with these regulations. Finally, the FDA also works with healthcare providers to ensure that GI drugs are prescribed and used appropriately. The agency provides information to healthcare professionals about the safe and effective use of these medications and monitors the use of these drugs to ensure that they are being used properly. By regulating the approval and use of GI drugs, the FDA and CMS help ensure that these medications are safe and effective for their intended use. This helps to ensure that patients receive the best possible care when it comes to treating their gastrointestinal conditions.

Committee Members
Speaker at Gastroenterology Conference - Gilles R G Monif

Gilles R G Monif

University of Florida, United States
Speaker at Gastroenterology Conferences - Tracy E Hill

Tracy E Hill

Ph.D. & Associates LLC, United States
Speaker at Gastroenterology Conferences - John Andrew Sutton

John Andrew Sutton

Gastria Ltd, United Kingdom
Gastro 2026 Speakers
Speaker at Gastroenterology Conference - Venturi Sebastiano

Venturi Sebastiano

AUSL-ROMAGNA, Italy
Speaker at Gastroenterology Conferences - Yaffa Machnes

Yaffa Machnes

Bar-Ilan University, Israel
Speaker at Gastroenterology Conference - Jose Luis Braga de Aquino

Jose Luis Braga de Aquino

Pontifical Catholic University of Campinas, Brazil
Speaker at Gastroenterology Conferences - Youcun Qian

Youcun Qian

Shanghai Institute of Nutrition and Health, China

Submit your abstract Today

Watsapp